Recent Developments in the Electrophysiology Markets

Wednesday, March 22, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 22, 2017 /PRNewswire/ --

FinancialBuzz.com News Commentary

The

global Electrophysiology (EP) market is growing rapidly due to the significant development and innovation in EP technologies. According to a report published by Allied Market Research, the global electrophysiology market was worth $3.42
billion
in 2015 and is expected to reach $8.271 billion by 2022, with a GAGR of 13.4%. Electrophysiology is a branch of cardiology and is used to diagnose abnormal heartbeats or arrhythmia. The report indicates that in addition to developments in innovative EP technologies, increased adoption of EP catheter ablation and growing number of EP labs are the main factors that drive the growth of the market. BioSig Technologies, Inc. (OTC: BSGM), Nevro Corporation (NYSE: NVRO), Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Siemens AG (OTC: SIEGY).

The electrophysiology ablation catheters are considered as one of the fastest-growing medical device segments, accounting for more than 35% of total electrophysiology market in 2015. Catheter ablation is a growing preference for the treatment of cardiac arrhythmias and has a high success rate. Radiofrequency and cryoablation are considered as the most widely used EP ablation catheters and are expected to witness significant growth in the near future due to advancement in the technology. As for the medical devices market itself, a report published by Lucintel indicates that the global medical device market is expected to reach an estimated $343 billion by 2021, and it is forecasted to grow at a CAGR of 4.6% from 2016 to 2021. 

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company developing a proprietary technology platform designed to improve the electrophysiology (EP) marketplace. Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

On March 17th, BioSig Technologies announced that, "It has signed a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration with Mayo builds upon the work realized under the Advanced Clinical Research Program that was signed with Mayo Clinic in March 2016.

BioSig intends to work closely with Dr. Samuel Asirvatham and K. L. Venkatachalam, leading Mayo electrophysiologists, to develop advanced clinical features and applications for its PURE EP System, as well as to leverage the company's core competency in physiologic signal processing to develop future technologies. Mayo is expected to contribute know-how, intellectual property and clinical support to the partnership. The company expects joint patent filings to come out of the relationship."

Nevro Corporation (NYSE: NVRO) is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro. The company has gone from pre-revenue in 2014 to $180 million of revenues and now with a $2.7 billion market capital.

The National Institute for Health and Care Excellence issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization therapy defibrillators (CRT-D) powered by EnduraLife™ Battery Technology for treating patients with heart failure. Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg.

Abbott Laboratories (NYSE: ABT) announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair procedures in the United States. MitraClip treats people with degenerative mitral regurgitation (DMR, also known as leaky heart valve), a serious condition involving a dysfunction of the heart's mitral valve, which regulates blood flow into the heart's main pumping chamber. The study analyzed data from the Transcatheter Valve Therapy registry involving nearly 3,000 DMR patients who were high-risk for surgery. Following minimally invasive implantation with MitraClip, patients had significant improvements, including 92.8 percent of patients achieving post-procedural mitral regurgitation severity grade of less than or equal to 2.

Siemens AG (OTC: SIEGY) has signed the U.S. Army's first energy savings performance contract at a government-owned, contractor-operated facility. Under this $11.8 million contract with the U.S. Army Corps of Engineers, Siemens will implement facility upgrades to enhance energy efficiency and reliability at the Joint Systems Manufacturing Center in Lima, Ohio, known to be one of the Army's largest energy consumers. The project includes a guarantee by Siemens that its improvements at the facility will save approximately $20 million or approximately 1.4 million British thermal units over the 15-year performance period. JSMC, which restores and repairs armored vehicles, such as the M1A2 Abrams Main Battle Tank, is owned by the Army but operated by General Dynamics Land Systems.

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com    

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content). FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated a total of twelve thousand dollars for financial news dissemination and PR services by a third party non affiliate for biosig technologies, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information: Media Contact: [email protected] +1-877-601-1879

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store